We are live on
!
Find out more
Antipodes Partners Portfolio holdings
AUM
$5.46B
Turnover
36.94%
1-Year Est. Return
26.64%
This Fund
S&P 500
This Quarter
Est. Return
+4.16%
1 Year Est. Return
+26.64%
3 Year Est. Return
+96.4%
5 Year Est. Return
+160.76%
10 Year Est. Return
–
AUM
$5.46B
AUM Growth
+$264M
(+5.1%)
Cap. Flow
+$147M
Cap. Flow
% of AUM
2.69%
Top 10 Holdings %
Top 10 Hldgs %
33.99%
Holding
157
New
31
Increased
42
Reduced
55
Closed
27
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
1.6
years
Top 20 Avg Time Held Equity + Options
2
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1.6
years
Top 20 Avg Time Held Equity only
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$90.4M |
| 2 |
Qorvo
QRVO
|
+$75.2M |
| 3 |
Meta Platforms (Facebook)
META
|
+$52.4M |
| 4 |
NVIDIA
NVDA
|
+$45.8M |
| 5 |
Capital One
COF
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Workday
WDAY
|
+$59M |
| 2 |
Microsoft
MSFT
|
+$55.4M |
| 3 |
Amazon
AMZN
|
+$50.3M |
| 4 |
Merck
MRK
|
+$40.2M |
| 5 |
Oracle
ORCL
|
+$31.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 27.87% |
| 2 | Technology | 14.3% |
| 3 | Healthcare | 11.52% |
| 4 | Consumer Discretionary | 9.78% |
| 5 | Energy | 8.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Steris
STE
$21.9B
| $128K | ﹤0.01% |
610
-2
| -0.3% | -$429 |
2025 Q1
5 quarters
|
|
102
Vertex Pharmaceuticals
VRTX
$129B
| $117K | ﹤0.01% |
235
+108
| +85% | +$47.9K |
2025 Q4
2 quarters
|
|
103
Waters Corp
WAT
$43.6B
| $103K | ﹤0.01% |
275
-95
| -26% | -$32.4K |
2025 Q3
3 quarters
|
|
104
Johnson Controls International
JCI
$89.4B
| $101K | ﹤0.01% |
693
-365
| -34% | -$51.5K |
2023 Q1
13 quarters
|
|
105
UnitedHealth
UNH
$365B
| $94.8K | ﹤0.01% |
+228
| New | +$84.5K |
2026 Q2
0 quarters
|
|
106
Natera
NTRA
$58.3B
| $87.4K | ﹤0.01% |
322
+42
| +15% | +$8.96K |
2025 Q1
5 quarters
|
|
107
Establishment Labs
ESTA
$1.83B
| $82.7K | ﹤0.01% |
+964
| New | +$69.3K |
2026 Q2
0 quarters
|
|
108
SI-BONE Inc
SIBN
$892M
| $81K | ﹤0.01% |
4,965
-599
| -11% | -$8.56K |
2025 Q4
2 quarters
|
|
109
Abbott
ABT
$181B
| $66.6K | ﹤0.01% |
+734
| New | +$67K |
2026 Q2
0 quarters
|
|
110
Avista
AVA
$3.03B
| $64K | ﹤0.01% |
1,565
-823
| -34% | -$33.9K |
2025 Q4
2 quarters
|
|
111
Autodesk
ADSK
$51.2B
| $59.7K | ﹤0.01% |
307
-13,151
| -98% | -$3M |
2024 Q2
8 quarters
|
|
112
GE Aerospace
GE
$324B
| $54.2K | ﹤0.01% |
145
+4
| +3% | +$1.25K |
2023 Q4
10 quarters
|
|
113
Ingersoll Rand
IR
$30.2B
| $50.8K | ﹤0.01% |
619
-325
| -34% | -$25.1K |
2023 Q4
10 quarters
|
|
114
MYR Group
MYRG
$4.45B
| $48.5K | ﹤0.01% |
97
-214
| -69% | -$87.9K |
2024 Q2
8 quarters
|
|
115
Humana
HUM
$51.9B
| $44.5K | ﹤0.01% |
+112
| New | +$31.9K |
2026 Q2
0 quarters
|
|
116
Elanco Animal Health
ELAN
$11.8B
| $42.3K | ﹤0.01% |
+1,720
| New | +$39.8K |
2026 Q2
0 quarters
|
|
117
Ormat Technologies
ORA
$5.51B
| $38.6K | ﹤0.01% |
354
-186
| -34% | -$23.1K |
2026 Q1
1 quarter
|
|
118
Tenet Healthcare
THC
$22.2B
| $38K | ﹤0.01% |
+203
| New | +$37.3K |
2026 Q2
0 quarters
|
|
119
Dianthus Therapeutics
DNTH
$4.17B
| $36.9K | ﹤0.01% |
379
+15
| +4% | +$1.31K |
2025 Q4
2 quarters
|
|
120
Qiagen
QGEN
$9.53B
| $36.8K | ﹤0.01% |
940
-1,049
| -53% | -$39K |
2025 Q1
5 quarters
|
|
121
908 Devices
MASS
$491M
| $34.7K | ﹤0.01% |
3,994
-408
| -9% | -$3.13K |
2025 Q1
5 quarters
|
|
122
Edwards Lifesciences
EW
$50.8B
| $34.3K | ﹤0.01% |
+379
| New | +$31.7K |
2026 Q2
0 quarters
|
|
123
Cigna
CI
$79B
| $34.2K | ﹤0.01% |
+124
| New | +$35K |
2026 Q2
0 quarters
|
|
124
Bio-Rad Laboratories Class A
BIO
$9.75B
| $33.2K | ﹤0.01% |
+113
| New | +$32.1K |
2026 Q2
0 quarters
|
|
125
McKesson
MCK
$116B
| $32.5K | ﹤0.01% |
+43
| New | +$34.1K |
2026 Q2
0 quarters
|
|
Similar funds
SCM
Antipodes Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Antipodes Partners held 157 positions worth $5.46B, up 5.1% from $5.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Antipodes Partners's Q2 2026 filing shows 31 new, 42 increased, 55 reduced and 27 closed positions. Its largest new stake was Booking.com: 530,062 shares worth $94.2M. The largest sale was Workday, an estimated $59M.
By sector, the portfolio is most concentrated in Utilities at 28% of assets, down from 29% a quarter earlier, followed by Technology and Healthcare.
- Antipodes Partners's largest Q2 2026 buy was Booking.com: 530,062 shares worth $94.2M.
- Antipodes Partners added most to Meta Platforms (Facebook) in Q2 2026, an estimated $52.4M increase.
- Antipodes Partners's biggest Q2 2026 reduction was Workday, cutting an estimated $59M.
- Antipodes Partners fully exited Oracle in Q2 2026, selling an estimated $31.2M.
- Antipodes Partners's ten largest holdings make up 34% of its $5.46B portfolio in Q2 2026.
- Antipodes Partners opened 31 new positions and closed 27 in Q2 2026.
- Antipodes Partners's portfolio value rose 5.1% quarter-over-quarter to $5.46B.
Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.